awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38925574-73D9B358-A0EE-4B3E-92E6-64C30F2D8659
Q38925574-73D9B358-A0EE-4B3E-92E6-64C30F2D8659
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38925574-73D9B358-A0EE-4B3E-92E6-64C30F2D8659
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
P2860
Q38925574-73D9B358-A0EE-4B3E-92E6-64C30F2D8659
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38925574-73D9B358-A0EE-4B3E-92E6-64C30F2D8659
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1dcbfe8e48915002f34eb68429b27a226d614352
P2860
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).